Compare Dow Inc (DOW) vs Dyne Therapeutics Inc. Common Stock (DYN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Dyne Therapeutics Inc. Common Stock — how do they compare? Dow Inc trades at $29.36 (market cap $20.59B), while Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B). The key difference: Dow Inc is far larger — about 7.2× Dyne Therapeutics Inc. Common Stock's market cap, and Dow Inc pays a 4.91% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 83 Days and Dyne Therapeutics Inc. Common Stock for 0 Days on average.
| DOW | DYN | |
|---|---|---|
Market Cap | $20.59B | $2.86B |
Volume | 5,540,746 | 3,341,579 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $26.78 |
52-Week Low | $20.95 | $14.60 |
Typical Hold Time | 83 Days | 0 Days |
Enterprise Value | $36.29B | $2.18B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $29.19, up 3.81% on the day, with a bearish technical signal and neutral oscillators. The company reported negative net income of -$2.62B in 2025, with declining revenue from $56.9B in 2022 to $40.0B in 2025. Recent earnings have beaten expectations, but profitability metrics like ROE (-7.86%) and net margin (-3.13%) remain weak. Analyst consensus is a $33.80 price target with mixed ratings (30.56% Buy, 55.56% Hold).
The outlook is cautious due to persistent margin pressures and high debt levels, though the dividend payout and earnings beats offer some stability. Risks include cyclical demand weakness and rising leverage, but the stock trades below consensus target, suggesting potential upside if operational improvements materialize.
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →
